ClinicalTrials.gg

Program

AK158D1

A development code.

Its studies are led by Akeso.

Furthest: phase 1, since Nov 1, 20261 company-led study, 1 open or runningNext primary completion: Apr 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso11 open or runningphase 1since Nov 1, 2026Nov 1, 2026Apr 30, 2028phase 1 · NCT07939919

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 1, 2026First study: phase 1 study in Solid Malignant TumorFirst studyNCT07939919 · 349 planned · China

Ahead

  1. Apr 30, 2028Primary completion: phase 1 study in Solid Malignant TumorNCT07939919

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07939919Solid Malignant Tumor · China1Not yet recruitingApr 30, 2028349

How it is read

Names in the registry

  • “AK158D1”, 1 entry

Codes read as this program: AK158D1.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 17, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.